Ask about this productRelated genes to: CDCP1 antibody
- Gene:
- CDCP1 NIH gene
- Name:
- CUB domain containing protein 1
- Previous symbol:
- -
- Synonyms:
- CD318, SIMA135
- Chromosome:
- 3p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-24
- Date modifiied:
- 2016-10-05
Related products to: CDCP1 antibody
Related articles to: CDCP1 antibody
- Breast cancer derived extracellular vesicles (EVs) mediate tumor progression through surface protein-dependent intercellular communication; however, their molecular heterogeneity remains poorly characterized. In this study, we employed a proximity-dependent barcoding assay (PBA) together with patient-derived organoid (PDO) models and identified CDCP1 as a key driver of EV-mediated oncogenesis. PBA-based surface proteomics revealed CDCP1 as the most upregulated protein in breast cancer-derived EVs compared with EVs from normal tissues. Clinical validation confirmed elevated CDCP1 expression in tumor tissues and matched EVs. PDOs generated from fresh clinical specimens recapitulated CDCP1 expression levels of the parental tumors and secreted CDCP1-enriched EVs. Functional experiments showed that CDCP1-knockdown EVs suppressed PDO proliferation and sensitized tumors to chemotherapy. Mechanistically, CDCP1-positive EVs promoted macrophage polarization toward an M2 phenotype, accompanied by upregulation of IL-10 and TGF-β and CCL22. Multiplex immunofluorescence confirmed that CDCP1-high tumors exhibited increased co-localization of CD68⁺ and CD163⁺ macrophages. These results establish CDCP1 as a master regulator of EV driven breast cancer progression, linking surface proteome remodeling to chemo-resistance and immunosuppressive microenvironment reprogramming. The integration of single-EV profiling and PDO modeling establishes a translational framework for targeting CDCP1 as a promising therapeutic target and a candidate biomarker for future liquid biopsy development in aggressive breast cancer subtypes. - Source: PubMed
Publication date: 2026/04/13
Liu YibingMa LiZhu TingWu DiLiu Yonglei - Joint use of multiple molecular layers can be useful to prioritize targets for mechanistic studies. Application of coronary disease in large populations is an emerging field. - Source: PubMed
Publication date: 2026/04/02
El-Sabawi BassimHuang XiaoningLin PhillipAnwar Mohammad YaserBetti MichaelKim NamjuPerry Andrew SPerera B Lakshitha AGajjar PriyaColangelo Laura AAmancherla KaushikSheng QuanhuZhao ShilinStolze LindsayFarber-Eger EricLandman Joshua MMiller Patricia ELiu Gabrielle YDas SumanWells Quinn STerry James GLloyd-Jones DonaldDas SaumyaKhan Sadiya SNorth Kari EBelow JenniferNayor MatthewKalhan RaviCarr John JeffreyGamazon Eric RShah Ravi V - Many studies have linked socioeconomic status (SES) and cardiovascular outcomes, yet the biologic mechanisms mediating these associations are only partially understood. The objective of this study was to identify molecular mediators of the association of low SES with coronary heart disease (CHD) and stroke. - Source: PubMed
Publication date: 2026/03/13
Odden Michelle CLiu XiaojuanShah Amil MYang YiminLamberson VictoriaBrody Jennifer ASitlani Colleen MHuber MattKalani RizwanShojaie AliRaffield Laura MGlover LáShauntáPalta PriyaKucharska-Newton Anna MPsaty Bruce MFloyd James S - Molecular counting technologies have greatly advanced biochemical analysis with ultrahigh sensitivity, excellent accuracy, and intuitive readouts. However, current methods remain limited by complex and time-consuming procedures, complicated data acquisition or analysis, or restricted multiplexing capabilities. Herein, we report an icosahedral DNA nanoprobe (IDNP)-mediated nanoflow cytometry (nFCM) assay platform that enables simple and rapid (approximately 30 min per sample) quantification of diverse biochemical analytes by bridging target recognition with direct molecular counting. The IDNP functioned as a "nano-signal converter", transforming nFCM-undetectable small-sized analytes into detectable IDNP-derived nanosignals, thereby allowing the molecular counting of these target analytes using nFCM. This developed IDNP-mediated nFCM assay platform successfully quantified multiple analytes, including miR-21, thrombin, and Pb, with results highly consistent with conventional methods (qPCR, ELISA, and ICP-MS, respectively). Furthermore, the platform was extended to achieve site-specific mA quantification, revealing upregulated methylation at specific sites of CDCP1 mRNA in bladder cancer cells and let-7a-5p miRNA in colorectal cancer cells compared with normal epithelial cells. Overall, this IDNP-mediated nFCM assay platform provides a powerful and versatile approach for rapid, simple, and multiplexed biochemical analysis, showing broad potential in biomedical and clinical applications. - Source: PubMed
Publication date: 2026/03/05
Zhou SuLi QinYan HongrongXiao ZixuanLiu LuyouLi JinQu Fengli - In two large, ethnically different prospective cohorts from the UK and Hong Kong, osteoporosis was associated with a higher risk of age-related cataracts, particularly in women. Proteomic mediation analysis identified five circulating proteins (MEPE, GDF15, TCN2, CDCP1, SIGLEC1) that may link osteoporosis to cataract development, warranting future mechanistic investigation. - Source: PubMed
Publication date: 2026/02/24
Zhang XiaowenKrishnamoorthy SuhasChong Kelvin K LMak Jonathan K LTan Kathryn Choon-BengKung Annie Wai-CheeWong Ian Chi-KeiZheng Hou-FengCheung Ching-Lung